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ABSTRACT
Owing to a unique set of attributes, human pluripotent
stem cells (hPSCs) have emerged as a promising cell
source for regenerative medicine, disease modeling
and drug discovery. Assurance of genetic stability
over long term maintenance of hPSCs is pivotal in this
endeavor, but hPSCs can adapt to life in culture by
acquiring non-random genetic changes that render
them more robust and easier to grow. In separate
studies between 12.5% and 34% of hPSC lines were
found to acquire chromosome abnormalities over time,
with the incidence increasing with passage number.
The predominant genetic changes found in hPSC lines
involve changes in chromosome number and structure
(particularly of chromosomes 1, 12, 17 and 20), remi-
niscent of the changes observed in cancer cells. In
this review, we summarize current knowledge on the
causes and consequences of aneuploidy in hPSCs
and highlight the potential links with genetic changes
observed in human cancers and early embryos. We
point to the need for comprehensive characterization
of mechanisms underpinning both the acquisition of
chromosomal abnormalities and selection pressures,
which allow mutations to persist in hPSC cultures.
Elucidation of these mechanisms will help to design
culture conditions that minimize the appearance of
aneuploid hPSCs. Moreover, aneuploidy in hPSCs may
provide a unique platform to analyse the driving for-
ces behind the genome evolution that may eventually
lead to cancerous transformation.
KEYWORDS human pluripotent stem cells (hPSCs),
culture adaptation, aneuploidy, cancer, genetic changes
INTRODUCTION
The goal of regenerative medicine is to enhance the healing
potential of the body or replace damaged tissues and
organs. This presents an immense challenge, but the basic
concepts and the technology appear poised to deliver this
aim. Central to these efforts are human pluripotent stem cells
(hPSCs), including embryonic stem cells (hESCs) derived
from human blastocysts (Thomson et al., 1998) and induced
pluripotent stem cells (hiPSCs) generated through repro-
gramming of differentiated cells (Takahashi et al., 2007), as
they can give rise to any cell type of the body. However, the
barriers along the translational pipeline are still numerous.
Firstly, an essential prerequisite for using hPSCs in clinical
applications is the maintenance of large numbers of homo-
geneous, undifferentiated stem cells in culture. Yet, sponta-
neous appearance of genetic and epigenetic variants
contributes to the phenotypic diversity of the individual cul-
tures. Furthermore, the existence of variant cells creates an
essential substrate for in vitro selection whereby mutations
that endow cells with improved growth outcompete their
normal counterparts and overtake the culture—a phenome-
non termed culture adaptation (Baker et al., 2007; Enver
et al., 2005). The mutational diversiﬁcation and clonal
selection of hPSCs in culture is an inevitability of basic
evolutionary principles. However, the presence of genetic
changes in hPSCs coupled with their increased growth rates
is reminiscent of the deﬁning features of cancer cells (Baker
et al., 2007). Viewed in this light, genetic changes are tem-
pering hope for the safe use of hPSCs in medicine.
The occurrence of non-random genetic changes in hPSC
cultures is now well established, but the genetic roadmap
that leads to the complex mutations remains obscure. With
hPSCs entering clinical trials (Schwartz et al., 2012), the
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need to identify driver mutations underpinning the culture
adaptation is particularly pressing. In addition to the clinical
relevance, hidden within the complex mutational proﬁles are
clues to the basic mechanisms governing stem cell fates.
Here, we provide an overview of the types of genetic chan-
ges commonly observed in hPSC cultures and their func-
tional consequences for hPSC phenotype and behavior.
Furthermore, we discuss the putative cellular mechanisms
underpinning the generation of the observed mutations.
Finally, we draw parallels between the genetic changes
observed in hPSCs with the ones commonly detected in
human cancers and early development, as integration of this
information will facilitate efforts to pinpoint the candidate
genes, molecular mechanisms and environmental factors
driving the culture adaptation.
GENETIC CHANGES IN hPSCs DURING IN VITRO
CULTURE
HESCs originate from the inner cell mass of early human
blastocysts where they exist only during a short window of
embryo development, prior to differentiating into the cells of
all three embryonic germ layers (Murry and Keller, 2008).
Placing the inner cell mass in vitro under the ﬁnely tuned
culture conditions prevents their imminent differentiation and
allows cells to self-renew seemingly indeﬁnitely whilst
retaining their differentiation potential (Thomson et al., 1998).
The shift from the in vivo niche to the life in an in vitro
environment is accompanied by marked transcriptional
changes (Yan et al., 2013) and is undoubtedly a stressful
event for cells. Conceivably, this may act as a trigger for
genome changes akin to (epi)genetic alterations associated
with the tissue culture in plants (McClintock, 1984). None-
theless, at least at the gross karyotype level, the majority of
hESC lines are normal upon derivation (Amps et al., 2011;
Thomson et al., 1998).
The production of hiPSCs by reprogramming of somatic
cells is a sequential process that starts by obtaining somatic
cells and placing them in vitro, followed by genetic manipu-
lation and selection/expansion of colonies with a hESC-like
phenotype (Takahashi et al., 2007). Thus, the sources of
genetic changes in hiPSCs include the cell of origin, the
reprogramming process and culture adaptation (Ronen and
Benvenisty, 2012).
The ﬁrst observation of recurrent karyotypic changes in
hESCs, involving gains of chromosomes 17q and 12 (Draper
et al., 2004), which are also commonly observed in embry-
onal carcinoma cells (the stem cells of malignant germ cell
tumours termed teratocarcinomas), prompted the notion that
culture adaptation may resemble transformation to malig-
nancy in cancer cells (Baker et al., 2007; Harrison et al.,
2007). Studies that followed highlighted additional frequent
aberrations, including gains of (parts of) chromosomes 1, 20
and X (Buzzard et al., 2004; Inzunza et al., 2004; Maitra
et al., 2005; Mitalipova et al., 2005; Spits et al., 2008).
Several groups also raised a possibility that the culture
conditions and passaging methods may inﬂuence the sta-
bility of hPSC karyotypes (Brimble et al., 2004; Buzzard
et al., 2004; Caisander et al., 2006; Mitalipova et al., 2005).
These observations have prompted large-scale international
efforts to generate a more comprehensive catalogue of the
mutational spectrum present in the hPSCs and interrogate
their possible relation to culture techniques. The Interna-
tional Stem Cell Initiative (ISCI) study screened 120 hESC
lines and 11 hiPSC lines from 38 different laboratories at an
early and late passage in culture (Amps et al., 2011),
whereas Taapken et al. (Taapken et al., 2011) analysed 40
hESC and 219 hiPSC lines from 29 laboratories. One of the
ﬁrst lessons gleaned from these large-scale studies is that
hESCs are commonly diploid soon after derivation and can
retain a normal karyotype after many passages (for example,
in the ISCI study 66% of lines remained normal). On the
other hand, a sizable proportion of cell lines examined did
show an abnormal karyotype (34% or 42/125 cell lines tested
in the ISCI study and 12.9% or 150/1,163 cultures karyo-
typed in the study by (Taapken et al., 2011)), demonstrating
that the occurrence of chromosome variations (numerical
and structural) is a common feature of hPSC culture. This is
particularly true for later passage cultures, which were
approximately twice as likely as early passage cultures to
contain cells with abnormal karyotypes (Amps et al., 2011).
Cells passaged by enzymatic methods were more likely to
acquire genetic abnormalities than the cells passaged
manually (Amps et al., 2011), but variants did occur in
manually passaged cultures, and the apparent greater sta-
bility following manual passaging may be a function of
population size, rather than an intrinsic effect on mutation
rate or selective advantage (Olariu et al., 2010). There was
no difference in the number of abnormalities detected after
culturing cells on mouse embryonic ﬁbroblasts versus cul-
turing the cells on Matrigel (Taapken et al., 2011).
With respect to the genomic regions commonly affected in
hPSCs, the large-scale studies echoed the earlier individual
reports showing non-random changes of chromosomes. For
example, of the abnormal hESC karyotypes in the ISCI
study, approximately 60% had involvement of at least one of
chromosomes 1, 12, 17 and 20 (Amps et al., 2011). Overall,
gain of chromosome material is markedly more common
than loss in culture adaptation of hPSCs. Recurrent dele-
tions (10p, 18q and 22q) do occur, but their signiﬁcance
remains to be elucidated (Amps et al., 2011; Laurent et al.,
2011). Comparison of genetic changes found in hiPSCs
versus the ones in hESCs highlighted some similarities but
also profound differences between two pluripotent cell types.
Similar to hESCs, the most common genetic alteration in
hiPSCs is trisomy 12 (Amps et al., 2011; Mayshar et al.,
2010; Taapken et al., 2011). However, trisomy 17 which is
frequently observed in hESC cultures is rarely seen in hiP-
SCs (Amps et al., 2011; Ben-David et al., 2011; Mayshar
et al., 2010; Taapken et al., 2011). On the other hand, gains
REVIEW Jie Na et al.
570 © The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn
P
ro
te
in
&
C
e
ll
of chromosome 8 are more frequent in hiPSC than hESCs
(Taapken et al., 2011). Despite these differences, the overall
frequency of chromosomal anomalies was similar between
hESC and hiPSC cultures (around 13% for both cell types)
(Taapken et al., 2011).
DETERMINING THE CAUSATIVE MUTATIONS IN
CULTURE ADAPTATION OF hPSCs
A useful method for pinpointing a minimal region of interest
and potentially gene(s) is the occurrence of recurrent chro-
mosome changes, and particularly recurrent chromosome
breakpoints. For example, the translocation between chro-
mosomes 9 and 22 (Philadelphia chromosome) (Nowell and
Hungerford, 1960; Rowley, 1973) led to identiﬁcation of the
BCR/ABL1 gene fusion (de Klein et al., 1982), which is
created at the join between the two chromosomes and is
now used for highly successfully targeted therapy in chronic
myeloid leukemia. In hPSCs, a recurrent ampliﬁcation of the
20q11.21 band has been reported in a number of studies,
both kaytoypically and sub-karyotypically (Amps et al., 2011;
Elliott et al., 2010; Laurent et al., 2011; Lefort et al., 2008;
Narva et al., 2010; Spits et al., 2008; Werbowetski-Ogilvie
et al., 2009). This has now been narrowed down to a minimal
region of about 500 kb that contains thirteen annotated
genes, only three of which are expressed in hPSCs: HM13,
ID1 and BCL2L1 (Amps et al., 2011). BCL2L1 has two iso-
forms, BCL-XL and BCL-XS, but the former is predominant
in hPSCs. The known anti-apoptotic role of BCL-XL isoform
(Boise et al., 1993) made this gene the prime candidate as a
driver mutation in the 20q11.21 region. Indeed, in mixing
experiments of normal cells with cells overexpressing any of
the three candidate genes from the region (HM13, ID1 or
BCL-XL), only BCL-XL provided cells with a selective
advantage, and this effect was diminished upon knocking
down the BCL-XL in cells with the ampliﬁed 20q11.21 region
(Avery et al., 2013).
The functional proof of BCL2L1’s involvement in culture
adaptation was greatly facilitated by a relatively small size of
the minimal amplicon on chromosome 20, narrowing down
the potential pool of candidate genes. Intriguingly, equivalent
minimal amplicons have not been identiﬁed for other com-
monly gained chromosomes. Although there are recurrent
chromosome regions gained (the long arm of chromosome
1, the short arm of chromosome 12, and the long arm of
chromosome 17 with a potential minimal amplicon at the
terminal 17q25 band) identiﬁed in the hPSCs, these are all
substantially sized regions (approximately 118, 34, and
11 Mb respectively; Ensembl) and the breakpoints are not
speciﬁc to individual chromosome bands (the breakpoint for
the chromosome 12 amplicon is centromeric). The use of
SNP analysis for detection of sub-karyotypic changes less
than 5 Mb in size did not provide any further narrowing down
of possible candidate genes/loci. This appears in some
respects discouraging, though this scenario is not an
uncommon feature of chromosome changes in cancers. For
instance, chromosome 8 is frequently gained, as a whole
chromosome in leukemias (e.g. found in 15%–20% of
myelodysplastic syndrome) (Mitelman, 2014) and as yet no
gene of interest has been identiﬁed. The absence of clear
minimal amplicons on chromosomes other than 20 may
reﬂect the need for several genes/pathways to be altered at
once in order to bring about the selective advantage.
Although we are yet to demonstrate this possibility in the
case of hPSCs, examples from less complex model organ-
isms support this hypothesis. For instance, in Candida albi-
cans resistance to antifungal compound ﬂuconazole is
acquired through gaining additional copies of the left arm of
chromosome V, which harbours two target genes acting
independently but in an additive manner to provide cells with
the resistance phenotype (Selmecki et al., 2006; Selmecki
et al., 2008).
Notwithstanding the need for further reﬁnement of can-
didate loci by genetic mapping, it is tempting to speculate on
candidate genes in addition to BCL2L1 that may be involved
in culture adaptation. A region of chromosome 12 that is
frequently ampliﬁed in hPSCs harbors several genes related
to pluripotency, including NANOG, DPPA3 and GDF3, as
well as cell cycle regulators such as CCND2. It is of note that
chromosome 12p also contained KRAS which is an onco-
gene abundantly expressed in testicular germ cell tumors as
well as a number of other cancer types (Alagaratnam et al.,
2011). Its homolog ERAS is highly expressed in mouse
ESCs and had been shown to promote tumor like property
during teratoma formation (Takahashi et al., 2003). A likely
candidate on chromosome 17q is an anti-apoptotic gene
BIRC5 (SURVIVIN). Genetic and pharmacological inhibition
of BIRC5 expression caused increased apoptosis of hPSCs
in vitro and in the teratomas (Blum et al., 2009).
THE ROLE OF ANEUPLOIDY IN CULTURE
ADAPTATION OF hPSCs: EVADING THE
SELECTIVE PRESSURE(S)
For a randomly mutated hPSC to persist and eventually
populate the entire culture with its own progeny, the acquired
mutation must allow the cell to break away from the normal
regulation of stem cell fates, i.e. self-renewal, differentiation
and death. For example, a mutant cell and its progeny have
to either proliferate more rapidly than the neighboring cells or
they have to be less prone to cell death and differentiation,
as either death or differentiation would lead to an irreversible
loss of stem cells (Fig. 1). In a set of experiments mimicking
the occurrence of sporadic mutants within a sea of normal
cells, Olariu et al. found that aneuploid hPSCs with repre-
sentative commonly observed karyotypic changes quickly
outcompeted their normal counterparts (Olariu et al., 2010).
One of the major hallmarks of adapted hPSCs is an
improved ability to create stem cell colonies following
Aneuploidy in PSC and implications for cancerous transformation REVIEW
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replating as single cells in cloning efﬁciency assays (Enver
et al., 2005; Harrison et al., 2007). Time-lapse tracking of two
different euploid lines and their aneuploid counterparts has
revealed at least three speciﬁc bottlenecks restricting the
colony expansion of normal cells which were alleviated in the
adapted cells to a large extent: (i) survival post-plating, (ii)
the ability of cells to re-enter the cell cycle, and (iii) survival of
daughter cells following mitosis (Barbaric et al., 2014). Anti-
apoptotic mechanisms are obvious candidates for allowing
mutant cells to progress though normally restrictive bottle-
necks. Indeed, characterization of BCL2L1 as a driver
mutation on chromosome 20q is consistent with this notion
(Avery et al., 2013), and a number of studies showed a
reduced apoptotic response of culture adapted cells (Avery
et al., 2013; Herszfeld et al., 2006; Yang et al., 2008).
Nonetheless, the links between culture adaptation and
apoptosis appear to be multifaceted. When Harrison et al.
stimulated extrinsic and intrinsic apoptotic pathways in the
normal and culture adapted cells, it was the adapted cells
that showed higher sensitivity to apoptosis (Harrison et al.,
2009). These observations support the notion that culture
adaptation may arise through various routes, as a result of
different selection pressures operating under speciﬁc culture
conditions (Harrison et al., 2009).
In addition to apoptosis, the loss of stem cells in culture
can arise through differentiation. Thus, culture adaptation
could be selecting against the ability of stem cells to differ-
entiate. In an extreme scenario, this may result in a “nulli-
potent” state in which cells may self-renew but no longer
differentiate, as is the case with many human embryonal
carcinoma cell lines (Andrews et al., 1980; Matthaei et al.,
1983). The ability of hPSCs to differentiate is a crux of many
potential applications of these cells, and changes in differ-
entiation ability would not only affect efﬁcient production of
differentiated cell types for cell therapy, but could also
hamper their application in disease modeling and drug dis-
covery (Goldring et al., 2011). Culture-adapted cells appear
capable of extensive differentiation, but their differentiation
deviates from their normal counterparts (Fazeli et al., 2011;
Werbowetski-Ogilvie et al., 2009). For example, cells with a
gain of chromosome 20q11.1-11.2 had a signiﬁcantly
reduced propensity to differentiate down the hematopoietic
lineage and in the neural differentiation experiments the
variant cells displayed more immature phenotypes along the
differentiation trajectory than their wild-type controls
(Werbowetski-Ogilvie et al., 2009). For some adapted cell
lines genetic changes resulted in the repression of extra-
embryonic endoderm differentiation (Fazeli et al., 2011).
Given that endoderm cells produce factors such as Bone
Morphogenetic Proteins (BMPs), which in turn induce dif-
ferentiation of hPSCs (Pera et al., 2004; Xu et al., 2002),
selection against spontaneous endoderm differentiation
might provide a mechanism for a selective advantage
(Fig. 1).
PARALLELS OF GENETIC CHANGES IN hPSCs
WITH HUMAN GERM CELL TUMOURS AND OTHER
CANCERS
A selective growth advantage imparted by an acquired
mutation is at the core of cancer development. Thus, the
process of culture adaptation of hPSCs is reminiscent of
malignant cell transformation. The recurrent mutations in
hPSCs are similar to the ones observed in testicular germ
cell tumours (TGCT) (Baker et al., 2007; Draper et al., 2004;
Harrison et al., 2007). Human TGCT are typically aneuploid
with multiple chromosomal rearrangements (Oosterhuis
et al., 1990). Seminomas, which constitute nearly half of all
TGCT, typically have a near 4N DNA content, whereas
nonseminomatous TGCT have nearer a 3N constitution,
leading to the suggestion that these tumours originate from a
tetraploid germ cell, with subsequent chromosomal rear-
rangement and loss during tumour progression. We previ-
ously suggested that abnormalities in the control of the
switch between mitosis and meiosis in primordial germ cells
A MUTATION THAT LEADS TO CELL DEATH
B
C MUTATION THAT LEADS TO 
IMPROVED SURVIVAL/PROLIFERATION
Cell death
Mutated cell is lost
from the culture
Stem cell culture
Mutated cell
Improved
survival
Clonal 
expansion
sllecdetatuMerutlucllecmetS
overtake the 
culture
Mutated cell
MUTATION THAT LEADS TO CELL DIFFERENTIATION
Differentiation
Stem cells 
differentiate 
Stem cell culture
Mutated cell
* *
*
*
* *
Differentiation 
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*
Figure 1. Possible scenarios of hPSC fates following an
acquisition of randommutations. (A) If a detrimental mutation
arises, the mutated cell will die and the mutation will not be
propagated in culture. (B) If a mutation causes cell differentia-
tion, the mutant cell will not only be lost from the stem cell pool,
but it may also start producing factors that induce differentiation
of other hPSCs. Due to the loss of stem cells through
differentiation, the mutated cell will not be selected for and its
progeny will be eventually lost from the culture. (C) If a mutation
causes improved survival and/or increased proliferation, the
mutated cell is likely to outcompete its neighboring cells and
populate the culture with its own progeny.
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as they populate the male genital ridge during embryonic
development might underlie the origins of aneuploidy in
TGCT (Adamah et al., 2006). Although hPSCs acquire
aneuploidy with respect to a few chromosomes, they rarely
reach the gross aneuploid state of typical human embryonal
carcinoma cells with a near triploid chromosome number
including multiple rearrangements (Wang et al., 1980). An
exception is the hESC line, CH-ES1, derived from a blas-
tomere of a cleavage stage embryo and containing multiple
chromosomal rearrangements (Hovatta et al., 2010). Among
the variant chromosomes of human embryonal carcinoma
cells, a gain of the short arm of chromosome 12, typically as
an isochromosome of 12p, is almost always present in
invasive tumours but less is often found in carcinoma in situ,
suggesting that this gain contributes to cancer progression
but not initiation (Atkin and Baker, 1982; Oosterhuis et al.,
1990). Gains of chromosome 17 and of chromosome 20 are
also reported (Amps et al., 2011; Avery et al., 2013; Skot-
heim et al., 2002). Studies of minimal amplicons of chro-
mosome 12p have suggested that a region that includes
NANOG, at 12p13.31 may be the critical region (Korkola
et al., 2006), though other regions such as 12p11.2-p12.1
have also been identiﬁed (Zafarana et al., 2003).
Although karyotypic changes in hPSCs seem to parallel
the ones found in TGCTs, it is worth noting that similar
mutations appear in other cancers. Chromosome 17 gain is
a common change in many cancers, and isochromosome of
the long (q) arm is suggestive of an aggressive clinical
course (Atlas of Chromos Cancer). Chromosome 17 is also
found in numerous recurrent translocations in leukemias and
solid tumours, such as the translocations with chromosomes
15 and 22 found in acute promyelocytic leukemia and der-
matoﬁbrosarcoma protuberans, respectively. Similarly, tri-
somy 12 is a common ﬁnding (16%) in chronic lymphocytic
leukemia (Dohner et al., 2000). Chromosome 1 rearrange-
ments resulting in duplication of the part or all of the long arm
as seen in hPSCs are found in up to 26% of abnormal
multiple myeloma cancers. Rearrangements of chromosome
20 observed in hPSCs are less frequently seen in cancers.
Interestingly, there is one report of a translocation between
chromosomes 20 and 6, resulting in a gene fusion between
BACH2 and BCL2L1 leading to overexpression of BCL2L1,
the candidate gene in the 20q11.21 amplicon identiﬁed in
hPSCs (Turkmen et al., 2011). This fusion was found in a cell
line from a patient with relapsed high-grade B-cell lym-
phoma, which showed a particularly aggressive course.
A key question that arises from the observed similarities
between genetic changes in hPSCs and cancer cells is
whether adapted hPSCs exhibit similar malignant properties
to cancer. Hanahan and Weinberg summarized the hall-
marks of cancer into the following categories: (i) self-sufﬁ-
ciency in growth signals, (ii) insensitivity to anti-growth
signals, (iii) evasion of apoptosis, (iv) sustained angiogene-
sis, (v) tissue invasion and metastasis, and (vi) unlimited
replicative potential (Hanahan and Weinberg, 2011).
Unlimited replicative potential in vitro is a deﬁning property of
karyotypically normal hPSCs, but additional hallmarks of
cancer cells have been noted in hPSCs with aneuploidy. For
example, a hPSC line with a gain of 20q11.1-11.2 showed
signs of self-sufﬁciency in growth signals, as it retained
undifferentiated phenotype even in the absence of basic
ﬁbroblast growth factor which is normally necessary for self-
renewal of hPSCs (Werbowetski-Ogilvie et al., 2009). Eva-
sion of apoptosis as noted in some culture adapted hPSCs is
also reminiscent of the key hallmarks of cancer (Avery et al.,
2013; Herszfeld et al., 2006; Yang et al., 2008). For purposes
of cell replacement therapies, a particularly concerning fea-
ture of culture adapted cells is the ability to form teratocar-
cinomas—tumors that in addition to differentiated derivatives
contain a remnant pool of undifferentiated stem cells, which
can be placed back into culture and grown as hPSCs
(Andrews et al., 2005; Blum and Benvenisty, 2009). As it is
unlikely that undifferentiated hPSC will be used to transplant
into patients, further rigorous testing is warranted to establish
whether any of the mutations in culture adapted hPSCs also
confer a growth advantage on their differentiated progeny.
MECHANISMS OFANEUPLOIDY IN hPSCs, CANCER
AND PREIMPLANTATION EMBRYOS: THE ROLE OF
SPINDLE ASSEMBLY CHECKPOINT
Generation of mutations is an essential prerequisite for cul-
ture adaptation. When considering mechanisms of mutations
in hPSCs, it is worth noting the differences in how the
recurrent chromosome changes occur. For example, chro-
mosome 12 is mostly gained as a whole chromosome or as
an isochromosome, whilst chromosome 1 and 17 are gained
via structural rearrangements such as intra-chromosomal
duplication and unbalanced translocations involving other
chromosomes in addition to trisomy and isochromosome
formation (Amps et al., 2011; Baker et al., 2007). This sug-
gests that chromosome 12 anomalies are more commonly
mitotic nondisjunction errors whilst the abnormalities of
chromosomes 1 and 17 may reﬂect their comparative rich-
ness in repetitive DNA sequences (e.g. segmental duplica-
tions) and occur via non-homologous recombination events
using these repetitive sequences and mis-repair of DNA
breaks.
Changes in chromosome numbers are often caused by
errors in separation of sister chromatids during mitosis. A
key regulatory mechanisms controlling accurate chromo-
some segregation to daughter cells is the spindle assembly
checkpoint (SAC) (also known as the mitotic checkpoint),
with conserved components from yeast to man (Musacchio
and Salmon, 2007). The major SAC components are enco-
ded by MAD (mitotic-arrest deﬁcient) genes MAD1, MAD2
and MAD3 (BUBR1 in humans), the BUB (budding unin-
hibited by benzimidazole) gene BUB1, and AURORA
KINASE B (Ipl1 in S. cerevisiae) (Musacchio and Salmon,
Aneuploidy in PSC and implications for cancerous transformation REVIEW
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2007). SAC becomes active as cells enter prometaphase,
when it monitors the interaction between kinetochores and
microtubules. Once all kinetochores have attached to the
bipolar spindle with equal tension, the SAC is inactivated
and cells are allowed to proceed through mitosis (Musacchio
and Salmon, 2007).
A number of studies have demonstrated that dysregula-
tion of SAC function perturbs various aspects of mitosis and
leads to the formation of aneuploid cells (Holland and
Cleveland, 2009). SAC components are commonly enriched
in cancer cells and have been linked to their active cell cycle
and unstable karyotypes. Overexpression or knock-down of
SAC proteins, such as MAD2, BUB1 and AURORA KINASE
B causes premature separation of sister chromatids, chro-
mosome bridging, and in some cases, cytokinesis failure
(Duijf and Benezra, 2013). If cells that have gone through
abnormal mitosis enter the next cell cycle, they often activate
the p53 dependent apoptosis pathway (Thompson and
Compton, 2010). A recent study by Crasta et al. (2012)
showed that in HeLa cells, micronuclei generated due to
mitotic chromosome segregation errors, contained whole
chromosomes that had persistent albeit aberrant DNA rep-
lication (Crasta et al., 2012). Defective DNA replication and
damage can lead to mutagenesis or chromosome pulveri-
zation within the micronuclei. As cells continue to divide,
when the nuclear envelop breaks down, micronuclei in a
subset of cells may join the mitotic chromosomes and rein-
tegrate into the nucleus of daughter cells (Crasta et al.,
2012). The reincorporation of fragmented micronuclei from
missegregated chromosomes may give rise to chromothrip-
sis, the phenomenon that involves complex genome rear-
rangements in a limited genomic region after one single
catastrophic event during cell cycle (Jones and Jallepalli,
2012).
In addition to cancer cells, human oocytes are particu-
larly prone to chromosome segregation errors during mei-
osis (Hassold and Hunt, 2001). Although SAC functions to
some extent in mammalian oocytes, it is insufﬁcient to
detect or correct unaligned chromosomes. This in turn
renders oocytes innately susceptible to aneuploidy, which is
made worse by an age-related reduction in key SAC reg-
ulators and factors that maintain chromosome and spindle
structure (Jones and Lane, 2013; Sebestova et al., 2012).
Chromosome segregation errors also happen frequently
post fertilization in mammalian preimplantation embryos.
Immunostaining studies revealed multipolar division marked
by multiple spindle poles (Chatzimeletiou et al., 2005).
Genome-wide assessment of copy number variations
(CNV) and single nucleotide polymorphisms (SNPs)
enabled detailed identiﬁcation of chromosome region gain,
deletion and aneuploidy. BAC array based cytogenetic
study of 3–4 day human IVF embryos (mostly at 8-cell
stage) found higher incidence of aneuploidy than those
found in early pregnancy or at birth (Vanneste et al., 2009).
This discrepancy may account for pregnancies lost before
their detection. Both cleavage and blastocyst stage IVF
embryos also showed frequent incidence of mosaic aneu-
ploidy, with a subset of blastomeres containing abnormal
number of chromosomes. Overall, these observations
suggested that mammalian oocytes and preimplantation
embryos may have a somewhat “leaky” SAC machinery
due to their unique cell cycle proﬁles and genes speciﬁcally
expressed in the gametes. The critical selection against
chromosome abnormalities does not appear to occur until
the time of implantation or shortly after, with mitotic aneu-
ploidy typically affecting signiﬁcant proportion of human IVF
embryos (Fragouli et al., 2013; Fragouli et al., 2008; Fra-
gouli and Wells, 2011; Vanneste et al., 2009). Despite the
prevalence of mosaic aneuploidy, hESCs derived from IVF
blastocysts are mostly karyotypically normal, suggesting
that aneuploidy may act as a negative selection barrier for
hESC derivation.
The molecular mechanisms of chromosome segregation
that leads to aneuploidy in hPSCs are poorly characterised.
The cell cycle of hPSC is relatively fast compared to many
somatic cells (Becker et al., 2006), and high expression of
SAC components may play a role in aberrant divisions as
was observed in cancer cells. Indeed, microarray studies
revealed that similar to cancer cells and preimplantation
embryonic cells, several SAC proteins such as MAD2 and
BUB1 are highly expressed in undifferentiated hESC and are
down-regulated upon differentiation (data obtained from
www.amazonia.transcriptome.eu). It also appears that in
contrast to differentiated cells, in which SAC triggers apop-
tosis as a response to microtubule poison-generated poly-
poidy, SAC in mouse and hPSCs is uncoupled from
apoptosis (Mantel et al., 2007).
We found that hPSCs highly express many SAC pro-
teins that are also enriched in oocytes and preimplantation
embryos, and can undergo abnormal mitosis during routine
culture (Fig. 2A). Moreover, inhibition of SAC function led to
the formation of micronuclei, which expressed DNA dam-
age marker γH2AX (Fig. 2B). These observations demon-
strated that hPSCs are indeed susceptible to erroneous
mitotic division, and warrant in-depth analysis of frequency
of their occurrence and underlying molecular mechanisms.
Based on well documented large-scale cytogenetic char-
acterizations of hPSCs and parallel ﬁndings from cancer
studies, we propose a model to explain recurrent karyotype
changes found in hPSC (Fig. 3): disturbing the function of
SAC components or mitosis machinery leads to defective
cell division with missegregated whole or partially broken
chromosomes and/or the formation of micronucleus with
extensive DNA damage and fragmentation. For many of the
cells, such changes will prove detrimental and result in cell
death. By chance, in a very small proportion of mutated
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cells the combination of genes affected will be such that it
endows them with survival advantage and preferential
retention during prolonged passaging. However, such
adaptation may hamper differentiation of hPSCs and
potentiate them to gain additional oncogenic genetic
changes.
FUTURE PERSPECTIVES
Although studies to date have revealed a plethora of genetic
changes in hPSCs, the true extent of genetic variation in
hPSCs is only likely to become apparent when we embark on
whole genome sequence analysis. The notion of acquiring
whole genome sequence of a signiﬁcant number of cells from
each culture condition may seem like a formidable task at the
moment, but given the rapid progress of the sequencing
technology and the concomitant drop in price, it is conceiv-
able that this type of analyses will become routine in the near
future. Nonetheless, the greater challenge will be decoding
the extraordinary breadth of the sequence data in the quest
to determine which of the numerous mutations in the genome
are causative and which are simply passenger events
(Stratton, 2011). Indeed, a decade since the ﬁrst report of the
recurrent chromosomal aberrations in hPSCs (Draper et al.,
2004) and a number of suggested candidate genes (Amps
et al., 2011; Laurent et al., 2011) only one gene, BCL2L1, has
been deﬁnitively shown to confer growth advantage to the
variant cells (Avery et al., 2013).
The advent of highly sensitive methods for mutation
detection raises a provocative question whether any muta-
tion detected should preclude the use of cells in various
in vitro applications and particularly in potential therapies. It
is also important to consider whether a mutation that does
not affect the phenotype and behavior of hPSCs may have
harmful effects once the cells are differentiated to a particular
lineage of interest and/or transplanted into a different niche
in vivo. Clearly, future efforts should be directed to develop
predictive tests of functionally important mutations. As
daunting as this task may seem, it will be of fundamental
importance for ensuring therapeutic safety of hPSCs. Par-
ticularly informative should be investigations of mechanisms
that lead to genetic changes in hPSCs as they may reveal
inherent weaknesses of mutant cells that could make them
amenable to therapeutic targeting. For example, an intrigu-
ing possibility is that aneuploidy triggers common transcrip-
tome changes (Torres et al., 2007), which would allow
targeted ablation of mutant cells. Such approach was
recently demonstrated in the case of trisomic mouse
embryonic ﬁbroblasts and aneuploid cancer cells, which
A B DNA
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Figure 2. Aberrant mitosis and micronucleus formation in hPSCs. (A) Immunostaining of euploid HUES1 hESCs for AURORA A
(a and b), AURORA B (c and d) and SURVIVIN (e, f). Nuclei are counterstained with DAPI. Panels (a and b) show an example of a
multipolar division with multipolar spindles. Note that AURORA A (green staining) is localized to all three spindle poles (white arrows
in b). Panels c–f show an example of a chromosomal bridge (white arrows in c and e). Note that AURORA B (d, green staining) and
SURVIVIN (f, green staining) are concentrated at the cleavage furrow and the lagging kinetochore (white arrows in d and e).
(B) Micronucleus formation (white arrow) in H9 hESCs after inhibition of AURORA B with 50 nm of AZD1152 for 24 h and release from
the inhibitor for 24 h. Micronucleus stained positive for γH2AX, a marker of DNA damage (green).
Aneuploidy in PSC and implications for cancerous transformation REVIEW
© The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn 575
P
ro
te
in
&
C
e
ll
were successfully eliminated from cultures by small com-
pounds that exerted antiproliferative effects only on aneu-
ploid cells but not their karyotypically normal counterparts
(Tang et al., 2011). In summary, improved ability to detect
mutations and assess their functional signiﬁcance, coupled
with targeted approaches to eliminate abnormal cells from
cultures will ensure positive prospects for translation of
hPSCs research into the clinic.
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Figure 3. Schematic view depicting putative mechanisms of chromosome number and structure changes due to aberrant
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